This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, A. C.
Right arrow Articles by Currie, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, A. C.
Right arrow Articles by Currie, B. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2004, p. 1763-1765, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1763-1765.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Outcomes of Patients with Melioidosis Treated with Meropenem

Allen C. Cheng,1,2 Dale A. Fisher,2,3 Nicholas M. Anstey,1,2,3 Dianne P. Stephens,2,4 Susan P. Jacups,1,2 and Bart J. Currie1,2,3*

Menzies School of Health Research, Charles Darwin University, Casuarina NT 0811, Northern Territory,1 Northern Territory Clinical School, Flinders University,2 Division of Medicine,3 Intensive Care Unit, Royal Darwin Hospital, Tiwi 0810, Darwin, Australia4

Received 9 November 2003/ Returned for modification 12 December 2003/ Accepted 1 February 2004

Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n = 153) despite a deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for >=14 days) is an alternative to ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with improved outcomes in patients with severe sepsis associated with melioidosis.

* Corresponding author. Mailing address: Menzies School of Health Research, Charles Darwin University, P.O. Box 41096, Casuarina NT 0811, Northern Territory, Darwin, Australia. Phone: 61889228196. Fax: 61889275187. E-mail: bart{at}menzies.edu.au.

Antimicrobial Agents and Chemotherapy, May 2004, p. 1763-1765, Vol. 48, No. 5
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.5.1763-1765.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Thamlikitkul, V., Trakulsomboon, S. (2009). In Vitro Activity of Doripenem against Burkholderia pseudomallei. Antimicrob. Agents Chemother. 53: 3115-3117 [Abstract] [Full Text]  
  • Cheng, A. C., Currie, B. J. (2005). Melioidosis: Epidemiology, Pathophysiology, and Management. Clin. Microbiol. Rev. 18: 383-416 [Abstract] [Full Text]  
  • Steward, J., Piercy, T., Lever, M. S., Nelson, M., Simpson, A. J. H., Brooks, T. J. G. (2005). Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection. J Antimicrob Chemother 55: 523-527 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»